Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Update

Atossa Therapeutics, Inc. (NASDAQ:ATOS) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totalling 12,350,000 shares, a growth of 17.0% from the March 31st total of 10,560,000 shares. Based on an average daily volume of 1,620,000 shares, the short-interest ratio is currently 7.6 days.

Atossa Therapeutics Price Performance

Shares of NASDAQ:ATOS remained flat at $1.53 on Monday. 600,130 shares of the company’s stock were exchanged, compared to its average volume of 1,385,205. The company’s fifty day moving average price is $1.44 and its two-hundred day moving average price is $1.02. Atossa Therapeutics has a 1 year low of $0.60 and a 1 year high of $2.31.

Atossa Therapeutics (NASDAQ:ATOS) last released its quarterly earnings results on Monday, April 1st. The company reported ($0.06) EPS for the quarter. On average, research analysts expect that Atossa Therapeutics will post -0.28 EPS for the current year.

Insider Transactions at Atossa Therapeutics

In related news, Director Jonathan Finn bought 25,000 shares of the firm’s stock in a transaction on Wednesday, April 10th. The shares were bought at an average price of $1.77 per share, with a total value of $44,250.00. Following the completion of the transaction, the director now directly owns 25,000 shares of the company’s stock, valued at approximately $44,250. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 7.80% of the company’s stock.

Hedge Funds Weigh In On Atossa Therapeutics

An institutional investor recently bought a new position in Atossa Therapeutics stock. PFG Investments LLC purchased a new position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 23,650 shares of the company’s stock, valued at approximately $43,000. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ATOS shares. StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, March 18th. Cantor Fitzgerald restated an “overweight” rating on shares of Atossa Therapeutics in a research report on Friday, January 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Atossa Therapeutics in a report on Tuesday, April 16th.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.